Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

Completed · Not applicable · Has a placebo group

Conditions studied: Autism

In brief

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: * Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. * Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. * Omega 3 fatty acids will be superior to placebo in improving functional ability.

Key facts

Study ID
NCT00467818
Run by
University of Medicine and Dentistry of New Jersey
People needed
17
Starts
2007-01-01
Expected to finish
2010-12-01
Last updated by the study team
2021-01-26

Who can join

Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.